Update on the pathophysiology of the epilepsies.
The pathophysiology of convulsive and non-convulsive epilepsies is discussed in its primary generalised forms. Focal, clinical and experimental epilepsies, with emphasis placed on the temporal lobe epilepsies (TLE) and their pathophysiologies are also reviewed. Neurotransmitters and neuromodulators and between them, the second messenger systems are considered in the generation, maintenance or inhibition of the epileptic discharge. Action mechanisms of the more classic antiepileptic drugs are briefly summarized along with the therapeutic strategies that might achieve the final control of abnormal discharges, including genetic control as a promising alternative in the current state of research. We emphasized the study of all type of glutamate and GABA receptors and their relation with mRNA editing in the brain. Some of the genetic studies which have been so fruitful during the last ten years and which have brought new insights regarding the understanding of epileptic syndromes are summarized in this article.
Ure
J A
JA
Department of Neurology, Borda Hospital, Buenos Aires, Argentina. jorgeure@hotmail.com
Perassolo
M
M
D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology / Q000627:therapeutic use; D004829:Epilepsy, Generalized / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*; D004830:Epilepsy, Tonic-Clonic / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology; D006801:Humans; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D018079:Receptors, GABA / Q000187:drug effects / Q000502:physiology*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*
D000927:Anticonvulsants; D018079:Receptors, GABA